The battle against extinction for the iconic Tasmanian devil has taken an intriguing turn with a new research initiative. The focus is on gene editing and vaccine development, offering a glimmer of hope for a species ravaged by a deadly facial cancer.
The Devil's Dilemma
Tasmanian devils, an apex scavenger in their ecosystem, have been fighting a losing battle against devil facial tumour disease (DFTD) since the 1990s. This contagious cancer has already claimed 80% of the wild population, spreading rapidly through bites during feeding and mating. The disease is caused by two separate cancers, DFT1 and DFT2, with the latter still spreading across the state.
A Two-Pronged Approach
In a bid to save the species, the Colossal Foundation and the University of Tasmania have joined forces. Their strategy is twofold: develop a vaccine and explore gene editing.
Vaccine Development
Andrew Flies and his team at the Menzies Institute for Medical Research have been working on an oral bait vaccine. The goal is to train the devil's immune system to fight both cancers. This vaccine, if successful, could protect wild devils without the need for individual trapping and injection. However, progress has been slow due to the challenges of working with an endangered species and a lack of marsupial-specific research tools.
Gene Editing Strategy
The second approach targets a gene called LZTR1, believed to be involved in the origin of the tumours. Researchers aim to test whether editing this gene can make devils more resistant to the cancers. This strategy could potentially enhance the effectiveness of the vaccine and provide a powerful tool in the fight against DFTD.
The Bigger Picture
The decline of Tasmanian devils has wider ecological implications. With their numbers dwindling, feral cats are spreading, impacting the ecosystem's balance. Colossal's expertise, gained through their thylacine revival project, is now being applied to living species, offering a unique perspective on conservation efforts.
A Race Against Time
While the vaccine shows promise, it still needs to pass safety trials before it can be tested on wild devils. This process could take time, and every day counts in the fight to save this species. The gene-editing strategy, if successful, could provide a faster and more effective solution, offering a much-needed boost to conservation efforts.
Conclusion
The Tasmanian devil's story is a reminder of the delicate balance of nature and the urgent need for innovative conservation strategies. This research partnership, with its dual approach, offers a glimmer of hope. It's a race against time, but with the right tools and expertise, we might just be able to save this iconic species from extinction. The world is watching, and the outcome could have far-reaching implications for conservation efforts globally.
